杭州博拓生物科技股份有限公司 2025年第三季度报告

Core Viewpoint - The company, Hangzhou Biotest Biotechnology Co., Ltd., is preparing for its third-quarter performance briefing scheduled for November 13, 2025, to provide insights into its operational results and financial status for the third quarter of 2025 [7][8]. Financial Data - The financial report for the third quarter of 2025 has not been audited [3]. - The report indicates that the company will implement a capital reserve transfer of 42,666,667 shares to shareholders, with a distribution of 4 shares for every 10 shares held, effective June 2025 [3]. Shareholder Information - The company assures that the quarterly report is accurate and complete, with no false records or significant omissions [2][5]. - There are no changes reported in the top ten shareholders or the status of shares available for lending [5][6]. Investor Engagement - The company is actively seeking questions from investors ahead of the performance briefing, allowing them to submit inquiries from November 6 to November 12, 2025 [10][13]. - The briefing will be held online, enabling real-time interaction between the company and investors [11][12]. Meeting Details - The performance briefing is set for November 13, 2025, from 9:00 AM to 10:00 AM, hosted on the Shanghai Stock Exchange Roadshow Center [11][12]. - Key personnel attending the meeting include the Chairman, General Manager, and Financial Director, among others [9].